

PRESS RELEASE

Grenchen, January 20, 2016

Excellent results for Thommen Medical Implants in a University of Bern* study, using the INICELL® surface in an early loading protocol

A recent clinical study* performed by Hicklin, Schneebeili, Chappuis, Janner, Buser and Brägger, demonstrated that Thommen Medical Implants with the INICELL® superhydrophilic surface can be successfully restored 21 days after implant placement. All implants were considered fully integrated at the 6-month follow-up examination, resulting in a survival and success rate of 100%.

This study confirms not only previously published results, but highlights additional benefits:

- Functional occlusal loading 21 days after implant placement is a safe and predictable treatment option when utilizing Thommen Medical Implants with the INICELL® superhydrophilic surface.
- No complications were reported within the observation period.
- The radiographic crestal bone loss analysis confirmed the marginal bone stabilization just beneath the machined (1 mm) implant collar.
- Patient satisfaction was very high, due to the shortened healing time experienced between implant placement and prosthetic reconstruction.

Based on the excellent clinical results, Thommen Medical Implants with the INICELL® superhydrophilic surface are currently unsurpassed for rapid and sustained tissue integration. Thommen Medical once again demonstrates its commitment to the needs of clinicians and their patients – which is always at the center of Thommen Medical's research activities – and its focus on ergonomics and simplicity in product development.

* Clin. Oral Impl. Res. 00, 2015; 1–9.



Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com

The press release is also available online:

<http://www.thommenmedical.com/en/downloads/media/press-releases.html>

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.